CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 136 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,135,039 | +88.5% | 76,126 | +10.3% | 0.00% | – |
| Q2 2023 | $601,986 | 0.0% | 69,035 | 0.0% | 0.00% | – |
| Q1 2023 | $601,986 | -99.9% | 69,035 | -37.0% | 0.00% | – |
| Q1 2021 | $497,678,000 | +1.5% | 109,621 | +28.3% | 0.00% | – |
| Q4 2020 | $490,369,000 | +202.7% | 85,430 | -22.0% | 0.00% | – |
| Q1 2020 | $162,024,000 | +27.3% | 109,476 | +68.6% | 0.00% | – |
| Q4 2019 | $127,305,000 | -64.8% | 64,951 | -8.0% | 0.00% | – |
| Q3 2019 | $361,595,000 | -24.1% | 70,624 | +6.2% | 0.00% | – |
| Q2 2019 | $476,341,000 | -93.7% | 66,528 | -88.3% | 0.00% | -100.0% |
| Q1 2019 | $7,579,015,000 | +79.8% | 570,709 | +6.6% | 0.01% | +50.0% |
| Q4 2018 | $4,214,275,000 | -35.1% | 535,486 | -8.7% | 0.00% | -20.0% |
| Q3 2018 | $6,495,484,000 | -14.8% | 586,235 | +3.2% | 0.01% | -16.7% |
| Q2 2018 | $7,626,398,000 | -1.0% | 568,286 | -4.2% | 0.01% | 0.0% |
| Q1 2018 | $7,705,876,000 | +42.1% | 593,216 | +0.6% | 0.01% | +20.0% |
| Q4 2017 | $5,423,307,000 | – | 589,490 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,254,502 | $20,741,000 | 14.54% |
| Versant Venture Management, LLC | 1,048,601 | $9,647,127,000 | 10.15% |
| Abingworth LLP | 1,147,077 | $10,553,000 | 7.65% |
| Omega Fund Management, LLC | 551,477 | $5,074,000 | 3.67% |
| Opaleye Management Inc. | 665,000 | $6,118,000 | 1.96% |
| DAFNA Capital Management LLC | 361,164 | $3,323,000 | 1.79% |
| Boxer Capital, LLC | 1,012,986 | $9,319,000 | 1.70% |
| Foresite Capital Management III, LLC | 600,000 | $5,520,000 | 1.55% |
| NEXTHERA CAPITAL LP | 536,568 | $4,936,000 | 0.91% |
| Perceptive Advisors | 2,685,882 | $24,710,000 | 0.82% |